title: Effect of oral prednisolone on visual outcomes and complications after scleral buckling.
abstract: OBJECTIVE
  To evaluate the effect of oral prednisolone on visual outcomes and complications of scleral buckling (SB) in phakic eyes with acute rhegmatogenous retinal detachment (RRD).
  
  
  METHODS
  In a randomized double-blind placebo-controlled trial, patients with acute RRD underwent SB. The treatment group received 1 mg/kg oral prednisolone for 10 days while the control group received placebo. Outcome measures included visual acuity (VA), retinal redetachment (re-RD), cystoid macular edema (CME), proliferative vitreoretinopathy (PVR), and other possible postoperative complications. Outcome measures were compared between groups with McNemar test.
  
  
  RESULTS
  Overall, 52 eyes of 52 subjects were enrolled into the study, which included 25 and 27 eyes in the treatment and placebo groups, respectively. Preoperatively, the extent and location of RD and rate of hypotony was comparable between the study groups. VA improvement (logMAR) was 0.75+/-0.61 overall: 0.85+/-0.62 in the treatment group versus 0.65+/-0.61 in the placebo group (p=0.36). Postoperative complications in the treatment and placebo groups included choroidal detachment, 3 versus 4 eyes (p=0.45), significant PVR, 1 versus 3 (p=0.33), and CME, 3 versus 5 eyes (p=0.39), respectively.
  
  
  CONCLUSIONS
  Postoperative oral prednisolone does not seem to improve the visual outcomes and complications of scleral buckling in simple phakic RRD.
authors.affiliation: Department of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, Shaheed Beheshti University (MC), Tehran, Iran. mhdehghan5@hotmail.com
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Dehghan
authors.forename: Hamid
authors.initials: H
authors.lastname: Ahmadieh
authors.forename: Masoud
authors.initials: M
authors.lastname: Soheilian
authors.forename: Mohsen
authors.initials: M
authors.lastname: Azarmina
authors.forename: Siamak
authors.initials: S
authors.lastname: Moradian
authors.forename: Ali R
authors.initials: AR
authors.lastname: Ramezani
authors.forename: Ali
authors.initials: A
authors.lastname: Tavallal
authors.forename: Jalil
authors.initials: J
authors.lastname: Naghibozakerin
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015862:Choroid Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011239:Prednisolone / Q000008:administration & dosage*; D012086:Reoperation; D012163:Retinal Detachment / Q000188:drug therapy / Q000601:surgery*; D012591:Scleral Buckling / Q000009:adverse effects*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone